ZyVersa Therapeutics Statistics Share Statistics ZyVersa Therapeutics has 4.77M
shares outstanding. The number of shares has increased by 344.37%
in one year.
Shares Outstanding 4.77M Shares Change (YoY) 344.37% Shares Change (QoQ) 90.31% Owned by Institutions (%) n/a Shares Floating 4.76M Failed to Deliver (FTD) Shares 30,295 FTD / Avg. Volume 0.54%
Short Selling Information The latest short interest is 359.25K, so 7.37% of the outstanding
shares have been sold short.
Short Interest 359.25K Short % of Shares Out 7.37% Short % of Float 7.38% Short Ratio (days to cover) 1
Valuation Ratios PE Ratio 0 Forward PE -0.01 PS Ratio 0 Forward PS 0.1 PB Ratio 0 P/FCF Ratio -0.16 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for ZyVersa Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.15,
with a Debt / Equity ratio of 0.
Current Ratio 0.15 Quick Ratio 0.15 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage -33858.18
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.34B Employee Count 7 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -6.75M Effective Tax Rate 0.07%
Stock Price Statistics The stock price has increased by -87.44% in the
last 52 weeks. The beta is 0.74, so ZyVersa Therapeutics's
price volatility has been higher than the market average.
Beta 0.74 52-Week Price Change -87.44% 50-Day Moving Average 0.62 200-Day Moving Average 1.12 Relative Strength Index (RSI) 40.83 Average Volume (20 Days) 5,593,145
Income Statement
Revenue n/a Gross Profit n/a Operating Income -9.14B Net Income -9.41B EBITDA -9.14B EBIT -9.15B Earnings Per Share (EPS) -8.48
Full Income Statement Balance Sheet The company has 1.53M in cash and 0 in
debt, giving a net cash position of 1.53M.
Cash & Cash Equivalents 1.53M Total Debt n/a Net Cash n/a Retained Earnings -112.63B Total Assets 20.99B Working Capital -9.89B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -7.56M
and capital expenditures 0, giving a free cash flow of -7.56M.
Operating Cash Flow -7.56M Capital Expenditures n/a Free Cash Flow -7.56M FCF Per Share -6.81
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ZVSA does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ZVSA is $240,
which is 43536.4% higher than the current price. The consensus rating is "Strong Buy".
Price Target $240 Price Target Difference 43536.4% Analyst Consensus Strong Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Apr 26, 2024. It was a
backward
split with a ratio of 1:10.
Last Split Date Apr 26, 2024 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -8.57 Piotroski F-Score 1
